Lithium, a mood-stabilizing agent for bipolar disorder, exerts its effects through an incompletely characterized mechanism thought to involve inhibition of inositol monophosphatase within the phosphoinositol cascade, and its pharmacokinetics are governed by renal excretion via sodium channels in the proximal convoluted tubule due to lithium's chemical similarity to sodium. Buspirone, an anxiolytic distinct from benzodiazepines and SSRIs, acts as a partial agonist at serotonin 5-HT1A receptors, a mechanism it shares with certain atypical antipsychotics, and is characterized pharmacologically by its lack of dependence liability and its interaction profile with alcohol and other CNS depressants. Both agents belong to psychiatric pharmacology, illustrating principles of narrow therapeutic index, ion-transport-mediated drug elimination, receptor-subtype-specific mechanisms of action, and the distinction between first-line and second-line pharmacotherapy within mood and anxiety disorders.
Lithium, a mood-stabilizing agent for bipolar disorder, exerts its effects through an incompletely characterized mechanism thought to involve inhibition of inositol monophosphatase within the phospho…